A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0683 in patients with advanced cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Vorinostat

Criteria

Inclusion Criteria:

• Patients 18 years or older

• Must agree to consume high fat meal and agree to fasting conditions

• Limit alcohol consumption

Exclusion Criteria:

• Patient has a history of drug or alcohol abuse within 5 years of start of study

• Patient is known to have HIV

• Patient has participated in another investigational study within 4 weeks of start of study

• Patient cannot stop taking certain medications or herbal remedies

• Patient will require immunologic, radiation, surgery, or chemotherapy during the study

• Patient requires frequent blood transfusions

• Female patient is pregnant or nursing

• Patient has an active Hepatitis B or C infection